On one hand, in addition to the block of mitotic progression, the centromere-specific damage induced by PLK1 inhibition might trigger further catastrophic mitotic responses in tumor cells, thus enhancing the efficacy of PLK1 inhibitor treatments. The gene discussed is PLK1; the disease is neoplasm.